Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Cell Senescence, Telomerase, and Senolytic Therapy
http://lidsen.com/journals/geriatrics/geriatrics-03-01-034
Telomerase and cancer: A complex relationship
http://www.lidsen.com/journals/geriatrics/geriatrics-05-01-156
A unified model of dementias and age-related neurodegeneration
https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12012
A podcast with David Sinclair and Joanna Masel
https://munkdebates.com/podcast/ageing
We can only guess, how much pressure must be in the boiler, by now. At the same time, their communications morale has dropped to an all-time low. They might eventually walk in on us, with lock, stock and barrel at once. We know, they‘re working to get RB underway, and to make a concrete proposal, regarding the merger. That should make for plenty of action and new prospects. If the stock actually goes lower still, it might be a very brief dip. It's grotesque already. All of this defies belief.
300 Million Euros for rejuvenation startups.
This guy is a German internet entrepreneur, founder of the Forever Healthy Foundation that hosts the Undoing Aging Conference, and he was involved in the seed funding of AgeX.
https://www.forever-healthy.org/news
What happened to the big plans with Juvenesence? I thought the billionaire was going to take over the biotech world. LCTX seems to have something resembling a weak pulse, but AGE seems to be a moribund research project.
No Time to Age: Uncoupling Aging from Chronological Time
https://www.preprints.org/manuscript/202104.0384/v1/download
This analysis may epically underestimate the company‘s potential, but our stock price history suggests that this is indeed, how many investors look at us. A knock-out announcement would still come in handy, and one that carries financial weight.
https://seekingalpha.com/article/4419082-agex-therapeutics-new-lygensis-merger-may-unlock-much-needed-value
I can’t say, I‘m the least bit surprised about today. This morning, it already looked like the market was completely unimpressed, and the stock fell, perhaps because the chart was already suggesting a re-test of the previous turning point. There‘s method to what we’re seeing here. The supercentenarian paper didn’t cut it either, nor did the news about the BAT study. What all of these events have in common, is that they don’t represent a tangible path to profitability, especially no timeframe. As I speculated in one of my previous posts, many factors might coincide here, and continue to keep the stock down. I‘d say, it‘s mostly the early-stage work, combined with funding needs, plus possibly a technology that is too mind-blowing to be understood, much less believed. On the other hand, we‘ve seen, how far meaningless events can take us, if there‘s only sufficient momentum.
The silver lining to this could be that the chart is far from uneventful, if you look past the day-to-day disappointments. Nothing suggests that what happened in October, was a common gap, or it probably would have been closed, months ago. Instead, the floor moved up to 1.41, where the stock stabilized in November.
I also think, there is a substantial possibility that the market could suddenly start playing this game in the opposite direction. Instead of constantly missing the prospects, and making a case like „90% of all drugs don’t make it past phase I“, the market could just as easily start pricing the stock, like there is no limit to their potential. This process might have already begun, only it‘s happening in slow motion. Once people take for granted that no run in AgeX will ever last, they might suddenly realize that they completely missed that it‘s already changed.
In the absence of hard facts on the balance sheet, the market might continue to knock us around. But substantial income might have already been placed in a far more distant future than it could turn out to be.
I still consider this level interesting. The possibility of being outperformed in the near-term, is ubiquitous. Perhaps the greatest challenge is the required patience. If the first question asked, is how many days it will take, to triple, the broad public might continue to ignore the AgeX stock. But this also means that many of them will end up chasing, when there finally is a lift-off.
Another aspect might be the lack of analyst coverage. A company, this small, remains under many radars. And almost no one will even dare to make any projections. They, too, could end up chasing. I‘m pretty sure that once we hit 20, someone will make the bold prediction that we might also hit 40. But to realize that 2 was a lot more interesting, that must be too much to ask. When standard indicators don’t apply yet, it seems like hardly anyone is ready to make a prediction anyway.
@Bob
The market runs its own affairs. The stock is obviously drawn to its recent turning point at 1.89. If they announced the exclusive licensing of their cancer applications, for an upfront of half a billion, the market would have no choice. But there is always some excuse. I suppose, if West introduced mice that can regrow eyes, ears and legs, and are expected to last 1,000 years, we’d drop to an all-time low. I wish I could load, but none of what I‘m trying to sell, is even trading today. And what I could sell, I don’t feel like selling.
Hi All, it's Bob from the Yahoo AGE message board setting up shop here in Investor's Hub. Peter, PAR75 and Felix - you all are welcome to DM me if you are set up over here. I've got an item I'd like to discuss with you.
Retards shorting premarket will end up getting burned up after the open.
Yummy! AGE $AGE
We shall see. Tomorrow could get interesting.
Great day of action! Held strong... next leg coming???
Agreed then back up we go! Low floater here with big money behind it!
Institutional investors make shorters
VERY NERVOUS.
Especially if they have a 50% stake.
They're covering now. IMO
There could be a huge squeeze here.
ExOr
Half the float locked up by institutional investors here. See where she goes.
AGE THIN ASK TO $6 AND 50% OF SHARES HELD BY INSTITUTION.
* * $AGE Video Chart 10-08-2020 * *
Link to Video - click here to watch the technical chart video
Thank you Crudeoil24.
Juvenescence Limited must be highly regarded in the industry.
AgeX Therapeutics shares are trading higher following an amended 13D filing showing Juvenescence Limited has a 50% stake in the company.
AGE
As far as this massive dol vol wants to take it until news flow hits glta
Someone in the great white north texted his buddies that they just struck a great vein!
Just joking!
But clearly someone knows something right glty!
Best of cont'd success to all here! Been some excellent monsters like this one dating all the way back to KODK which has been an awesome addition to the HOT OTC casino we've had for most of this year!
Does anybody have an idea why the huge volume and price spikes with AGE today?
to the moon
Keep on banking Pedro! We got trade em not marry em when they're awakenin' hotties right cheers>>>$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
I was in at $2.50 -- I got scared -- and I sold at $3.00
Looking for another entry
MA$$IVE big boy vol pouring in folks!!!
Insane in the membrane weeeeeeeeeeeeeeeeeee
AGE ASK THIN ALL THE WAY TO $5.
what in the heck happened?
* * $AGE Video Chart 05-29-2020 * *
Link to Video - click here to watch the technical chart video
Confusion regarding AgeX and LCTX collaboration/competition
LCTX states
"We have entered into three separate agreements with entities in the cell therapy space for the license, development, manufacture and sale of products based on our broad cell therapy platform and technologies."
Subsequently on 12/30 AgeX states...
" Going forward we plan to strengthen our capacity of executing on external licensing and collaboration deals with third parties as well as in-house cell therapy product development."
Does anyone have a clear idea or a website that explains who is selling what? When AgeX split from BTX/LCTX who owns the rights to which patents, etc.?
Any clarification would be greatly appreciated.
NOTE: I'm posting this on both the LCTX and the AgeX sites.
Agex & Juvenescence publish in a peer-reviewed journal "Regenerative Medicine"
LINK: https://www.agexinc.com/investors-media/single-news-story/?id=6626
Article:
Logo Logo Logo Logo Logo
About Us
Leadership
Technology
Pipeline
Investors
Contact Us
AgeX Therapeutics and Juvenescence Publish Paper on Engineering Strategies for Universal Cells and Provide in Vivo Observation on Immunotolerance UniverCyteTM Technology Platform
10/30/2019
Paper published in peer-reviewed journal Regenerative Medicine
UniverCyteTM platform aims to utilize proprietary, novel, modified form of immunomodulatory molecule HLA-G to generate universal allogeneic cells to enable off-the-shelf therapeutics without the need for immunosuppressants
Previously unpublished in vivo observation signals that UniverCyte-modified allogeneic cells may be potentially hypoimmunogenic in humanized mouse model
Co-authors are Drs. Nafees Malik and Gregory Bailey of AgeX and Juvenescence, Dr. Annalisa Jenkins of AgeX, and Jim Mellon, Chairman of Juvenescence
ALAMEDA, Calif. & DOUGLAS, Isle of Man--(BUSINESS WIRE)--Oct. 30, 2019-- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Juvenescence, a life sciences company developing therapeutics and technologies to treat diseases of aging and to increase human longevity, announce the publication of a new paper in the peer-reviewed scientific journal Regenerative Medicine. The paper is on the engineering of allogeneic cells to be hypoimmunogenic (universal), so as not to produce an immune response. The strategies reviewed in the paper include deletion of human leukocyte antigen (HLA) class Ia/II proteins, expression of HLA class Ib molecules, and manipulation of immune checkpoints.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191030005329/en/
In addition, the paper presents a previously unpublished in vivo observation on allogeneic human pluripotent stem cells (hPSCs) modified with AgeX’s proprietary immunotolerance technology, UniverCyteTM. In humanized mice (those with a functional human immune system), UniverCyte-positive hPSCs formed larger and heavier tissue compared to controls. This observation provides support for the premise that UniverCyte-expressing tissue was potentially hypoimmunogenic and might have escaped recognition by a functional human immune system and continued to grow. Further work is required to substantiate this preliminary in vivo finding.
“Hypoimmunogenic allogeneic cells are the Holy Grail in regenerative medicine, and a number of accomplished researchers have made great strides toward engineering them over the last few years,” commented Dr. Nafees Malik, Chief Operating Officer at AgeX, Head of Cell & Gene Therapy at Juvenescence (a major investor in AgeX), and lead author on the paper. “This is a huge area of focus for us at AgeX, via our UniverCyte technology platform. In support of our own research and as a service to the overall field, we decided to put together this paper, analyzing all the leading strategies to engineer universal cells and encapsulating them in one paper.”
Dr. Malik’s co-authors on the paper are Gregory Bailey, MD, Chairman of the Board of Directors of AgeX and CEO of Juvenescence; Annalisa Jenkins, MBBS, FRCP, who serves on the Board of Directors of AgeX; and Jim Mellon, Chairman of Juvenescence.
Mr. Mellon added, “AgeX’s UniverCyte technology platform will not only be important to the company in developing in-house therapies, it may also be transformative for the wider cell therapy industry via collaborations and licensing deals. It is quite conceivable that in the near future, allogeneic cell therapies may potentially need to be universal to be clinically and commercially competitive.”
AgeX is developing its UniverCyte technology platform at its new 15,700-square-feet R&D facility, in the San Francisco Bay Area, which has current good manufacturing practices (cGMP)-capable manufacturing capacity.
“Universal cells would help us and others to fulfill the original vision of cell therapy,” said Dr. Bailey. “Thus, I am pleased that my colleagues at AgeX and Juvenescence have put together this paper, as it should be of considerable benefit to researchers, possibly enabling them to accelerate their progress.” He added, “AgeX’s UniverCyte technology uses a novel, modified form of the tolerogenic molecule HLA-G, which in nature plays a key role in preventing a mother from rejecting her semi-allogeneic baby.”
The paper is being published online ahead of print on Wednesday, October 30, 2019. It may be found here.
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem® and UniverCyte™ manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a whole host of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeX’s revolutionary longevity platform named induced Tissue Regeneration (iTR™) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem® is AgeX’s delivery technology to stably engraft PureStem cell therapies and slowly release iTR molecules in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to form licensing and partnership agreements around its broad IP estate and proprietary technology platforms for non-core clinical applications.
For more information, please visit www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.
About Juvenescence
Juvenescence is a life sciences company developing therapies to increase healthy human longevity. It was founded by Jim Mellon, Dr. Greg Bailey and Dr. Declan Doogan. The Juvenescence team are highly experienced drug developers, entrepreneurs and investors with a significant history of success in the life sciences sector. Juvenescence will create, partner with or invest in new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures to develop therapeutics for longevity. Juvenescence believes that recent advances in science have greatly improved our understanding of the biology of aging and seeks to develop therapeutics with the possibility of slowing, halting or potentially reversing elements of aging.
Forward-Looking Statements
Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in AgeX’s reports filed with the Securities and Exchange Commissions (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191030005329/en/
Source: AgeX Therapeutics, Inc.
AgeX Therapeutics, Inc.
Dr Nafees Malik, COO
nmalik@agexinc.com
Bill Douglass (Media)
Gotham Communications, LLC
bill@gothamcomm.com
(646) 504-0890
Juvenescence
David Ellam, CFO
david@juvenescence.ltd
AgeX Therapeutics, Inc. 2018
GLTA
HCIT
Yet another new Low of $2.05, all the way from the $5.00+++ When will this stop already, anyone?
GLTA
HCIT
Cincy, yes it is very quiet here and I agree on your post that there is a milestone in 6 months. Hope they are on time for that. I haven't sold but did add a few weeks ago to AGE - GLTU
HCIT
Very quiet here. Everyone sell and leave??
I was actually surprised at the details on the September 9 presentation at Rodman.
Unlike their earlier presentations, this presentation looks more like a legitimate business presentation. They even include a section regarding ANTICIPATED SIX MONTHS MILESTONES. Now let's us see how accountable to fulfilling those MILESTONES. Let's hope there are more ACCOMPLISHED checks than DELAYED OR DROPPED messages after 6 months.
I'm particularly interested in the RENELON category after all the hoopla a couple of years ago.
If we look at last quarterly reports of LCTX, AGE, OCX, do we find any real commercial activity. I see managerial musical chairs, lots of questionable scientific experiments, location moving and disruption, ringing of bells at stock exchanges, and no meaningful timelines leading to revenues.
I once had a hope that Juvenescene would bring some business focus and expertise that would change the culture that has led this BTX empire from a scientists playground into almost oblivion.
Question! Why do any of you still own any of these stocks. I'm preparing to jump ship after waiting, waiting, waiting???
What hopes or catalysts over the next 12 months are convincing to you that make you maintain your positions in any of these enterprises...given the pathetic nature of these quarterly reports?
I don't think they would cringe bobby2. IMO< it's called rejuvination at it's best with a dash of evolutionary regeneration. Just my opinion - gltu
HCIT
I *think* their general plan is to:
(a) Grow early age replacement cells in the lab
(b) Use exosomes to deliver a signal for cells to temporarily express Telomerase (rejuvenates ends of DNA strands for endless copies)
(3) Insert those cells into the body where needed, along with the Small Molecule Cocktail iTR157 (turns on genes for temporary tissue regeneration vs scarring)
I guess this is their version of coming with all guns blazing. Take cells still capable of regeneration, program them to keep their Telomeres completely intact and drug them to continue to regenerate tissues even further.
And I'm also guessing they would cringe to hear the way I just explained things.
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
156
|
Created
|
06/16/11
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |